MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers BULL
News headline image
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Provides Routine Update on Annual Filings
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Closing of its Rights Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Commencement of Rights Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story